ROS1 and non-small cell lung carcinoma: Recently, performing a hybrid capture-based NGS assay on plasma of 18 ROS1 positive NSCLC patients relapsing after crizotinib, Dagogo-Jack and colleagues identified SNVs possibly associated with resistance in 44% of cases (five patients with ROS1 G2032R, one with ROS1 L2026M, one with PIK3CA E545K, and one with BRAF V600E) [86].